SG11201701669PA - Flavivirus virus like particle - Google Patents
Flavivirus virus like particleInfo
- Publication number
- SG11201701669PA SG11201701669PA SG11201701669PA SG11201701669PA SG11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA SG 11201701669P A SG11201701669P A SG 11201701669PA
- Authority
- SG
- Singapore
- Prior art keywords
- particle
- flavivirus virus
- flavivirus
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462048897P | 2014-09-11 | 2014-09-11 | |
PCT/JP2015/004623 WO2016038895A1 (en) | 2014-09-11 | 2015-09-10 | Flavivirus virus like particle |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701669PA true SG11201701669PA (en) | 2017-04-27 |
Family
ID=55453731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701669PA SG11201701669PA (en) | 2014-09-11 | 2015-09-10 | Flavivirus virus like particle |
Country Status (14)
Country | Link |
---|---|
US (1) | US10098943B2 (en) |
EP (1) | EP3191589A4 (en) |
JP (1) | JP6942309B2 (en) |
KR (1) | KR102532832B1 (en) |
CN (1) | CN106687590B (en) |
AR (1) | AR101814A1 (en) |
AU (1) | AU2015313650B2 (en) |
BR (1) | BR112017004770A8 (en) |
CA (1) | CA2960102C (en) |
MX (1) | MX2017003117A (en) |
PH (1) | PH12017500450A1 (en) |
SG (1) | SG11201701669PA (en) |
TW (1) | TWI695842B (en) |
WO (1) | WO2016038895A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
WO2016210127A1 (en) * | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
CU20200018A7 (en) * | 2017-09-11 | 2020-11-30 | Tengen Biomedical Company | MAMMAL SPECIFIC DEFECTIVE GROWTH ARBOVIRUS |
CN113429479B (en) * | 2018-04-04 | 2023-03-10 | 中国科学院微生物研究所 | High-sensitivity yellow fever virus humanized monoclonal antibody and application thereof |
KR101970963B1 (en) * | 2018-12-19 | 2019-04-23 | 주식회사 엠디헬스케어 | DNA aptamer binding specifically to yellow fever virus envelope protein domain III (YFV EDIII) and uses thereof |
WO2020242388A1 (en) * | 2019-05-28 | 2020-12-03 | Chiang Mai University | Mature virus-like particles of flaviviruses |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
KR100251505B1 (en) | 1991-11-16 | 2000-05-01 | 장 스테판느 | Hybrid protein between cs from plasmodium and hbsag |
US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
JPH07291996A (en) | 1994-03-01 | 1995-11-07 | Yuu Honshiyo | Polypeptide related to programmed cell death in human, dna coding the same, vector consisting of the same dna, host cell transformed with the same vector, antibody of the same polypeptide and pharmaceutical composition containing the same polypeptide or the same antibody |
AU716466B2 (en) | 1995-09-27 | 2000-02-24 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
EP1054973A1 (en) | 1998-02-11 | 2000-11-29 | Maxygen, Inc. | Antigen library immunization |
JP2002503478A (en) * | 1998-02-11 | 2002-02-05 | マキシジェン, インコーポレイテッド | Targeting gene vaccine vectors |
PT1210428E (en) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, a receptor for b7-4, and uses therefor |
JP4080423B2 (en) | 2001-05-30 | 2008-04-23 | トランジェーヌ、ソシエテ、アノニム | Adenovirus protein IX and its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
US7476390B2 (en) * | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
US20050237480A1 (en) * | 2002-05-13 | 2005-10-27 | The Regents Of The University Of California | Chemical modifications to polymer surfaces and the application of polymer grafting to biomaterials |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
WO2005000881A2 (en) | 2003-05-29 | 2005-01-06 | United States Army Medical Research Institute For Infectious Diseases | Live attenuated viral vaccines for eastern equine encephalitis virus |
JP4506301B2 (en) | 2003-09-30 | 2010-07-21 | ブラザー工業株式会社 | Ink cartridge and inkjet printer |
CA2547511A1 (en) | 2003-12-01 | 2005-07-28 | Dow Global Technolgies Inc. | Recombinant icosahedral virus like particle production in pseudomonads |
US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
AU2007200847B2 (en) * | 2004-07-27 | 2010-06-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
PT1802336E (en) | 2004-10-14 | 2011-11-15 | Glaxosmithkline Biolog Sa | Malaria prime/boost vaccines |
JP4819792B2 (en) | 2005-02-16 | 2011-11-24 | 国立大学法人東京工業大学 | Modified viral capsid proteins and uses thereof |
SI1907000T2 (en) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Methods and compositions for the treatment of persistent HIV infections by inhibiting the programmed cell death 1 (PD-1) pathway |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
CU23586A1 (en) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS |
WO2007100098A1 (en) | 2006-03-03 | 2007-09-07 | Kyoto University | Multimer of extracellular domain of cell surface functional molecule |
AU2007291936B2 (en) | 2006-08-30 | 2012-09-27 | Artes Biotechnology Gmbh | Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
WO2009079185A2 (en) | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
US9353353B2 (en) | 2008-11-26 | 2016-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles (VLPs) prepared from chikungunya virus structural proteins |
US20120219579A1 (en) | 2009-09-18 | 2012-08-30 | Fraunhofer Usa Inc. | Virus like particles comprising target proteins fused to plant viral coat proteins |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
CN101948850A (en) * | 2010-08-13 | 2011-01-19 | 中国疾病预防控制中心病毒病预防控制所 | Preparation method and application of virus-like particles of dengue viruses |
WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
CN103561771B (en) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | The immunization therapy redirected |
CN103796676B (en) | 2011-06-17 | 2017-09-12 | 伯哈拉特生物技术国际有限公司 | The vaccine combination of datum hole Kenya Strain comprising inactivation |
US9284356B2 (en) * | 2011-07-12 | 2016-03-15 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of a west nile virus CD4 T cell epitope and use thereof |
CN102321639B (en) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | Preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV) and its application |
IN2014CN03925A (en) * | 2011-10-25 | 2015-07-03 | Florida Gulf Coast University | |
BR112014020052B8 (en) | 2012-02-16 | 2023-04-18 | Vlp Therapeutics Llc | VIRUS-TYPE PARTICLE, COMPOSITIONS, ANTIBODY PRODUCTION METHOD AND USE OF SAID PARTICLE |
CN108912215A (en) | 2012-04-02 | 2018-11-30 | 北卡罗来纳-查佩尔山大学 | Method and composition for dengue virus epitope |
PL2850431T3 (en) | 2012-05-16 | 2018-09-28 | Immune Design Corp. | Vaccines for hsv-2 |
US20150265695A1 (en) * | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
JP6734651B2 (en) | 2013-06-03 | 2020-08-05 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | Malaria vaccine |
US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
WO2015139784A1 (en) | 2014-03-18 | 2015-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
JP6824154B2 (en) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーVLP Therapeutics, LLC | Virus-like particles containing the modified envelope protein E3 |
US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
CN107427571A (en) | 2014-12-31 | 2017-12-01 | ***合众国,由健康及人类服务部部长代表 | Novel multivalent vaccine based on nano particle |
EP3309251A4 (en) | 2015-06-12 | 2019-03-13 | Mie University | Human parainfluenza type 2 virus vector and vaccine |
WO2016210127A1 (en) | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
EP3322441A4 (en) | 2015-07-16 | 2018-12-19 | Bharat Biotech International Limited | Vaccine compositions |
EP3324979B1 (en) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Infectious disease vaccines |
CN106085974B (en) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | A kind of zika virus pseudovirion and preparation method thereof |
-
2015
- 2015-09-10 SG SG11201701669PA patent/SG11201701669PA/en unknown
- 2015-09-10 CA CA2960102A patent/CA2960102C/en active Active
- 2015-09-10 EP EP15840429.3A patent/EP3191589A4/en active Pending
- 2015-09-10 AU AU2015313650A patent/AU2015313650B2/en active Active
- 2015-09-10 WO PCT/JP2015/004623 patent/WO2016038895A1/en active Application Filing
- 2015-09-10 KR KR1020177009567A patent/KR102532832B1/en active IP Right Grant
- 2015-09-10 US US14/850,399 patent/US10098943B2/en active Active
- 2015-09-10 MX MX2017003117A patent/MX2017003117A/en unknown
- 2015-09-10 BR BR112017004770A patent/BR112017004770A8/en active IP Right Grant
- 2015-09-10 JP JP2017513835A patent/JP6942309B2/en active Active
- 2015-09-10 CN CN201580048888.9A patent/CN106687590B/en active Active
- 2015-09-11 TW TW104130067A patent/TWI695842B/en active
- 2015-09-11 AR ARP150102897A patent/AR101814A1/en unknown
-
2017
- 2017-03-09 PH PH12017500450A patent/PH12017500450A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10098943B2 (en) | 2018-10-16 |
JP2017528139A (en) | 2017-09-28 |
EP3191589A1 (en) | 2017-07-19 |
AR101814A1 (en) | 2017-01-11 |
BR112017004770A8 (en) | 2023-04-11 |
WO2016038895A1 (en) | 2016-03-17 |
KR102532832B1 (en) | 2023-05-16 |
TWI695842B (en) | 2020-06-11 |
CN106687590A (en) | 2017-05-17 |
TW201612190A (en) | 2016-04-01 |
BR112017004770A2 (en) | 2017-12-12 |
AU2015313650A1 (en) | 2017-04-13 |
CA2960102C (en) | 2023-10-24 |
CN106687590B (en) | 2021-08-03 |
CA2960102A1 (en) | 2016-03-17 |
AU2015313650B2 (en) | 2021-07-08 |
US20160074501A1 (en) | 2016-03-17 |
EP3191589A4 (en) | 2018-05-09 |
JP6942309B2 (en) | 2021-09-29 |
KR20170055513A (en) | 2017-05-19 |
PH12017500450A1 (en) | 2017-07-31 |
MX2017003117A (en) | 2017-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257480A1 (en) | Engineered virus | |
HK1255670A1 (en) | Modified virus-like particles of cmv | |
GB2535253B (en) | Compositions and methods | |
IL252216A0 (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
HK1231471A1 (en) | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2- | |
GB201405614D0 (en) | Particles | |
GB201405834D0 (en) | Oncolytic virus | |
SG11201700968PA (en) | Formulation comprising particles | |
GB201406608D0 (en) | Virus | |
PL3152226T3 (en) | Modified cyclopentapeptides and uses thereof | |
GB201506381D0 (en) | Embolization particle | |
SG11201701669PA (en) | Flavivirus virus like particle | |
GB201412841D0 (en) | Particles | |
GB2540240B (en) | Catalyst particle | |
GB201411526D0 (en) | Powder | |
HK1253030A1 (en) | Piv5-based amplifying virus-like particles | |
GB201419572D0 (en) | Virus | |
GB2577405B (en) | Particle | |
SG11201609908VA (en) | Virus reduction method | |
ZA201708393B (en) | Large particles | |
GB201402915D0 (en) | Compositions and methods | |
GB201708709D0 (en) | Virus like particle | |
GB201600380D0 (en) | Modified virus | |
GB201522013D0 (en) | Virus | |
GB201516936D0 (en) | Virus |